Insulin-Like Growth Factor Binding Proteins in Kidney Disease

Shuqiang Wang; Kun Chi; Di Wu; Quan Hong

doi:10.3389/fphar.2021.807119

Insulin-Like Growth Factor Binding Proteins in Kidney Disease

Front Pharmacol. 2021 Dec 22:12:807119. doi: 10.3389/fphar.2021.807119. eCollection 2021.

Authors

Shuqiang Wang^{1

2}, Kun Chi¹, Di Wu¹, Quan Hong¹

Affiliations

¹ Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases, Beijing, China.
² Department of Nephrology, Peking University Shenzhen Hospital, Shenzhen, China.

Abstract

The seven members of the insulin-like growth factor (IGF) binding protein family (IGFBPs) were initially considered to be the regulatory proteins of IGFs in the blood circulation, mainly as the subsequent reserve for bidirectional regulation of IGF function during environmental changes. However, in recent years, IGFBPs has been found to have many functions independent of IGFs. The role of IGFBPs in regulating transcription, inducing cell migration and apoptosis is closely related to the occurrence and development of kidney disease. IGFBP-1, IGFBP-3, IGFBP-4 are closely associated with diabetes and diabetic nephropathy. IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6 are involved in different kidney disease such as diabetes, FSGS and CKD physiological process as apoptosis proteins, IGFBP-7 has been used in clinical practice as a biomarker for early diagnosis and prognosis of AKI. This review focuses on the differential expression and pathogenesis of IGFBPs in kidney disease.

Keywords: IGFBPs; biomarker; function; kidney disease; mechanism.

Publication types

Review